A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid receptor agonists. The structure of buprenorphine allows for multimechanistic interactions with opioid receptors μ, δ, κ, and opioid receptor-like 1. Buprenorphine is considered a partial agonist with very high binding affinity for the μ-opioid receptor, an antagonist with high binding affinity for the δ- and κ-opioid receptors, and an agonist with low binding affinity for the opioid receptor-like 1 receptor. Partial agonism at the μ-opioid receptor does not provide partial analgesia, but rather analgesia equivalent to that of full μ-opioid receptor agonists. In addition, unlike full μ-opioid receptor agonists, buprenorphine may have a unique role in mediating analgesic signaling at spinal opioid receptors while having less of an effect on brain receptors, potentially limiting classic opioid-related adverse events such as euphoria, addiction, or respiratory depression. The pharmacokinetic properties of buprenorphine are also advantageous in a clinical setting, where metabolic and excretory pathways allow for use in patients requiring concomitant medications, the elderly, and those with renal or hepatic impairment. The unique pharmacodynamic and pharmacokinetic properties of buprenorphine translate to an effective analgesic with a potentially favorable safety profile compared with that of full μ-opioid receptor agonists for the treatment of chronic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 2×
“For example, GPCR ligands can selectively activate different intracellular G-protein signaling pathways, recruit barrestin, or both to varying degrees [29, 34].”
BackgroundUniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283
Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., Walwyn, W., Kieffer, B. L., Takeshima, H., Carroll, F. I., Maidment, N. T., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10331.2003 · Cited by 211
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation
Cahill, C. M., Walwyn, W., Taylor, A. M. W., Pradhan, A. A. A., & Evans, C. J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.08.002 · Cited by 122
Averting opioid-induced respiratory depression without affecting analgesia
Dahan, A., van der Schrier, R., Smith, T., Aarts, L., van Velzen, M., & Niesters, M. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002184 · Cited by 115
Cited by
Opioids and pituitary function: expert opinion
Gadelha, M. R., Karavitaki, N., Fudin, J., Bettinger, J. J., Raff, H., & Ben-Shlomo, A. (2022) · Pituitary · doi:10.1007/s11102-021-01202-y · Cited by 27
Self-citation
Metadata
- Authors
- Gudin, J., & Fudin, J.
- Venue
- Pain and Therapy
- Published
- 2020-01-28
- Volume
- 9
- Issue
- 1
- Pages
- 41-54
- ISSN
- 2193-651X (ISSN-L)
- 2193-8237
- OpenAlex
- W3004185853
- Cited by
- 172
- References
- 15
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. https://app.cochat.ai/papers/10.1007/s40122-019-00143-6
- The paper
- Gudin, J., & Fudin, J. (2020). A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. Pain and Therapy. https://doi.org/10.1007/s40122-019-00143-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.